Have sanctioned algorithms replaced empiric judgment in the selection process of antiarrhythmic drugs for the therapy for atrial fibrillation?
- James A. Reiffel MD
- … show all 1 hide
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Treatment of atrial fibrillation (AF) includes rate control, anticoagulation, rhythm control, and therapy of any underlying structural heart disease and/or AF precipitant. Rhythm control, restoration of and maintenance of sinus rhythm (NSR), is required in patients who remain significantly symptomatic despite rate control. Rhythm control generally employs antiarrhythmic drugs (AAD). When the selection of AADs was limited, and included only class IA agents, the choice of drug to use was empiric, guided by anticipated tolerance and compliance. Now, with multiple classes of AADs available and with a better understanding of organ toxic and proarrhythmic risks, algorithms to guide drug selection have become both popularized and sanctioned. Notably, although such algorithms are now the standard of care and the norms to which practitioners should be held regarding the selection of an AAD for AF management, they have not removed empiricism and clinical judgment from the AAD selection process. Clinical decision making is still required to select from among any group of drug options as listed in the published algorithms, and to select the dosing regimen to use. Prior history, dosing frequency, desirability of à-blocking effect, electrolyte status, renal function, concomitant therapies, site of initiation, and anticipated patient compliance are also all nonalgorithmic issues in the decision process.
- Hagens VE, Van Gelder IC, Crijins HJGM: The RACE study in perspective of randomized studies on management of persistent atrial fibrillation. Card Electrophysiol Rev 2003, 7:118–121. CrossRef
- American Heart Association: Heart Disease and Stroke Statistics 2003 Update. Dallas, TX: American Heart Association; 2002.
- Cain ME: Atrial fibrillation-rhythm or rate control. N Engl Med 2002, 347:1822–1823. CrossRef
- Feinberg WM, Blackshear JL, Laupacis A, et al.: Prevalence, age distribution, and gender of patients with atrial fibrillation: analysis and implications. Arch Intern Med 1995, 155:469–473. CrossRef
- Wyse DG, Waldo AL, DiMarco JP, et al.: Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Investigators. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002, 347:1825–1833. The largest and most important study comparing a strategy of rate versus rhythm control. Survival was not enhanced with a sinus rhythm strategy. Strokes were still significant with a sinus rhythm strategy if warfarin was stopped or the INR was less than 2.0, even in sinus rhythm. CrossRef
- Fuster V, Ryden LE, Asinger RW, et al.: American College of Cardiology/American Heart Association/European Society of Cardiology Board. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: executive summary. A Report of the American College of Cardiology /American Heart Association Task Force on Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients with Atrial Fibrillation): developed in collaboration with the North American Society of Pacing and Electrophysiology. J Am Coll Cardiol 2001, 38:1231–1266. The current international guidelines for the evaluation and management of AF are detailed in this position paper. CrossRef
- Olsson SB, Executive Steering Committee on behalf of the SPORTIF III Investigators: Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomized controlled trial. Lancet 2003, 362:1691–1698. Keep your eye out for the release of ximelagatran which, in the SPORTIF trials had similar efficacy to warfarin with lesser bleeding, no requirement for coagulation monitoring, and virtually no food or drug interactions. CrossRef
- Halpern JL, Executive Steering Committee, SPORTIF III and V Study Investigators: Ximelagatran compared with warfarin for prevention of thromboembolism in patients with nonvalvular atrial fibrillation: Rationale, objectives, and design of a pair of clinical studies and baseline patient characteristics (SPORTIF III and V). Am Heart J 2003, 146:431–438. CrossRef
- Van Gelder IC, Hagens VE, Bosker HA, et al., and the Rate Control versus Electrical Cardioversion for Persistent Atrial Fibrillation Study Group: A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med 2002, 347:1834–1840. CrossRef
- Carlsson J, Miketic S, Windeler J, et al., and the STAF Investigators: Randomized trial of rat-control versus rhythm-control in persistent atrial fibrillation: the Strategies of Treatment of Atrial Fibrillation (STAF) study. J Am Coll Cardiol 2003, 41:1690–1696. CrossRef
- Hohnloser SH, Kuck KH: Randomized trial of rhythm or rate control in atrial fibrillation: the Pharmacological Intervention in Atrial Fibrillation Trial (PIAF). Eur Heart J 2001, 22:801–802. CrossRef
- Cardiac Arrhythmia Suppression Trial (CAST) Investigators: Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med 1989, 321:406. Increased our awareness of the risks of proarrhythmia and changed the way we viewed AADs in patients with heart disease. CrossRef
- Waldo AL, Camm AJ, deRuyter H, et al.: Survival with oral dsotalol in patients with left ventricular dysfunction after myocardial infarction: rationale, design, and methods (the SWORD trial). Am J Cardiol 1995, 75:1023–1027. CrossRef
- Torp-Pedersen C, Moller M, Bloch-Thomsen PE, et al.: Dofetilide in patients with congestive heart failure and left ventricular dysfunction. Danish Investigations of Arrhythmia and Mortality on Dofetilide Study Group. N Engl J Med 1999, 341:857–865. CrossRef
- Julian DG, Camm AJ, Frangin G, et al.: Randomized trial of effect of amiodarone on mortality in patients with left ventricular dysfunction after recent myocardial infarction: EMIAT. European Myocardial Infarct Amiodarone Trial Investigators. Lancet 1997, 349:667–674. CrossRef
- Cairns JA, Connolly SJ, Roberts R, Gent M: Randomized trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular depolarizations: CAMIAT. Canadian Amiodarone Myocardial Infarction Arrhythmia Trial Investigators. Lancet 1997, 349:675–682. CrossRef
- Camm AJ, Karam R, Pratt CM: The azimilde post-infarct survival evaluation (ALIVE) trial. Am J Cardiol 1998, 81:35D-39D. CrossRef
- Reiffel JA: Selecting an antiarrhythmic agent for atrial fibrillation should be a patient-specific, data-driven decision. Am J Cardiol 1998, 82:72N-81N. CrossRef
- Prystowsky EN: Management of atrial fibrillation: therapeutic options and clinical decisions. Am J Cardiol 2000, 85:3D-11D. CrossRef
- Reiffel JA, Camm AJ, Haffajee CI, et al.: International consensus roundtable on atrial fibrillation. Cardiol Rev 2000, 17:1–19.
- Pritchett EL, Page RL, Carlson M, et al., and the Rythmol Atrial Fibrillation Trial (RAFT) Investigators: Efficacy and safety of sustained-release propafenone (propafenone SR) for patients with atrial fibrillation. Am J Cardiol 2003, 92:941–946. Propafenone in a sustained-release, twice daily formulation appears to have greater convenience and more uniform efficacy and tolerance than the old immediate-release, three times daily formulation. CrossRef
- Meinertz T, Lip GY, Lombardi F, et al. and the ERAFT Investigators: Efficacy and safety of propafenone sustained release in the prophylaxis of symptomatic paroxysmal atrial fibrillation (The European Rythmol/Rytmonorm Atrial Fibrillation Trial [ERAFT] Study). Am J Cardiol 2002, 90:1300–1306. CrossRef
- Reiffel JA: Issues in the use of generic antiarrhythmic drugs. Curr Opin Cardiol 2001, 16:23–29. For narrow therapeutic index drugs, caution should be the rule when considering formulation substitution. For antiarrhythmics, there has been documentation of recurrence, proarrhythmia, and death in association with formulation substitution. CrossRef
- Reiffel JA: Formulation substitution and other pharmacokinetic variability: under appreciated variables affecting antiarrhythmic efficacy and safety in clinical practice. Am J Cardiol 2000, 85:46D-52D. CrossRef
- Reiffel JA: Drug choices in the treatment of atrial fibrillation. Am J Cardiol 2000, 85:12D-19D. CrossRef
- Have sanctioned algorithms replaced empiric judgment in the selection process of antiarrhythmic drugs for the therapy for atrial fibrillation?
Current Cardiology Reports
Volume 6, Issue 5 , pp 365-370
- Cover Date
- Print ISSN
- Online ISSN
- Current Medicine Group
- Additional Links
- Author Affiliations
- 1. Division of Cardiology, Columbia-Presbyterian Hospital, 161 Fort Washington Avenue, 10032, New York, NY, USA